BF844 通过诱导 CLRN1N48K 转运至质膜,减轻 USH3 突变的 CLRN1N48K 相关的听力损失,并在体内表现出显著的保留听力作用。
产品编号: MS-U63723 CAS No.: 1404506-35-9 分子式: C21H19ClN4O 分子量: 378.85
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

BF844 通过诱导 CLRN1N48K 转运至质膜,减轻 USH3 突变的 CLRN1N48K 相关的听力损失,并在体内表现出显著的保留听力作用。

生物实验数据

生物活性 BF844 alleviates USH3 mutation-associated CLRN1N48K-related hearing loss by inducing CLRN1N48K transport to the plasma membrane and exhibits significant hearing preservation effects in vivo.
体外研究
(In Vitro)

BF844 (compound 3) (0.846 μM) effectively inhibits HSP60 activity (87.07±27.70% inhibition) and moderately inhibited HSP90 (40.06±19.10% inhibition).
BF844 (2.90 μM; 24 h) induces about 6% of total CLRN1N48K to be transported to the plasma membrane in C1, D1, D6 cells.
BF844 (2.90 μM; 24 h) effectively increases the amount of non-glycosylated CLRN1 and non-glycosylated CLRN1 is effectively transported to the plasma membrane in C1 and D1 cells.

体内研究
(In Vivo)

BF844 shows good penetration into the retina and cochlea in vivo.
BF844 (10 mg/kg; i.p.) shows significantly preserves hearing in Tg;KI/KI mice.

Animal Model: Juvenile mice
Dosage: 3, 10 mg/kg (3 mg/kg for P6 (post-natal day 6) mice, 10 mg/kg for P20 (post-natal day 20) mice)
Administration: I.p.
Result: Showed AUC values were determined to be 1.76 μM.h and 1.98 μM.h.
Animal Model: P30 Tg;KI/KI C57BL/6J mice
Dosage: 30 mg/kg
Administration: I.p.; daily from P30 to P45
Result: Showed significantly preserves hearing with the median threshold of sound intensity in log scale was 57.5–67.5 dB SPL and about 1,000 times more sensitive hearing compared to untreated controls at P55.
Animal Model: P10 Tg;KI/KI C57BL/6J mice
Dosage: 10 mg/kg
Administration: I.p.; 10 mg/kg every other day and gradually escalated the dose up to 20 mg/kg at P28. From P30 to P45, mice received 30 mg/kg daily
Result: Showd the median threshold of sound intensity in log scale was 55, 42.5 and 37.5 dB SPL lower at 8, 16 and 32 kHz at P55, respectively.

化学信息

分子量 378.85
分子式 C21H19ClN4O
CAS No. 1404506-35-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础